Mergers, acquisitions and partnerships
Acquisitions, licensing deals, collaborations and major funding in pharma and biotech. Sources on every story.
AstraZeneca, insitro Strike $1.5B AI Drug Discovery Deal
AstraZeneca has entered a strategic collaboration with AI-driven biotech insitro worth up to $1.5 billion to develop therapeutics for cardiometabolic diseases.
PBM Copay Programs Shift Financial Risk to Specialty Pharmacies
Specialty pharmacies face mounting financial pressures as PBM benefit designs transfer risk downstream while maintaining therapy access control, raising sustainability concerns.
FDA Selects Seven Manufacturers for PreCheck Pilot Program
FDA's new PreCheck Pilot Program enrolls seven pharmaceutical companies in an initiative designed to strengthen domestic manufacturing and streamline quality assessments.
Pharmaceutical Fine Chemicals Market Surges to $179.87B in 2026
The pharmaceutical fine chemicals sector is experiencing exceptional growth, with market value jumping $15B to reach $179.87B in 2026, signaling robust drug manufacturing expansion.
Dietary Supplements Market Set to Reach $324.88B by 2034
New market analysis projects the global dietary supplements industry will grow at 6.37% annually through 2034, driven by consumer wellness trends and aging populations.
Big Pharma Turns to China for Next-Gen Cancer Drug Innovation
Major pharmaceutical companies are increasingly licensing oncology compounds from Chinese biotech firms, signaling a strategic shift in global drug development sourcing.
Cell Culture Supplements Market Set to Triple by 2033 on Biotech Boom
Cell culture supplements market projected to surge from $2.74B to $7.14B by 2033, driven by biopharmaceutical manufacturing expansion and cell therapy development.
Pharma 5.0 Market Set to Hit $59B by 2035 Amid Digital Revolution
The pharmaceutical industry's Pharma 5.0 evolution—combining AI, automation, and personalized medicine—will expand from $9.83B to $59.14B by 2035 at 22% CAGR.
J&J's $14.6B Intra-Cellular Buy Signals CNS Therapy Land Grab
Johnson & Johnson's mega-acquisition of Intra-Cellular Therapies marks the second major biopharma deal in one day, highlighting intense consolidation in CNS therapeutics.
Patent Cliff to Wipe Out $500B+ in Drug Sales as Industry Braces
Pharmaceutical industry faces historic patent expirations threatening over $500 billion in annual sales, triggering strategic shifts in R&D, M&A, and competitive positioning.
Royalty Pharma Commits $100M to Zealand's Rusfertide Program
Royalty Pharma's $100M investment in Zealand Pharma's polycythemia vera treatment signals growing confidence in rare disease therapeutics and innovative funding models.
P&G Acquires Thorne in Major Supplement Consolidation Play
Procter & Gamble's acquisition of premium supplement brand Thorne marks a strategic shift as big pharma enters the $431B wellness market amid ongoing industry consolidation.
Dietary Supplement Market Surges to $431.7B by 2033 Amid FDA Oversight Gaps
The global dietary supplement market is projected to nearly double by 2033, reaching $431.7B, even as FDA lacks pre-market approval authority over new products.
Pharma Manufacturing Market Set to Hit $1.2 Trillion by 2034
Global pharmaceutical manufacturing capacity projected to nearly double to $1.226 trillion by 2034, driven by biologics expansion and infrastructure investment.
Nestlé Enters GLP-1 Nutrition Market as Category Expands
Nestlé's strategic move into GLP-1-companion nutrition signals the category's evolution from niche supplements to mainstream market, reshaping pharmaceutical partnerships.
China's NMPA Records 40 First-Time Approvals in 2025 as Innovation Accelerates
China's pharmaceutical regulator has processed 40 novel drug approvals in 2025, signaling the country's emergence as a major innovation hub reshaping global drug development.
Big Pharma Deepens China Biotech Investments Despite Tensions
Major pharmaceutical companies are expanding partnerships with Chinese biotech firms, signaling confidence in innovation potential and market opportunities despite geopolitical headwinds.
Sector Rotation Drives 83% Pharma Stock Surge as Investors Flee Tech
Portfolio managers pivot from mega-cap tech to pharmaceutical innovation plays, signaling major capital reallocation that could reshape pharma valuations and M&A activity.
Tarsus Pharmaceuticals Acquires Alkeus for $450M in Strategic Expansion
Tarsus Pharmaceuticals announces $450M acquisition of Alkeus Pharmaceuticals, marking continued consolidation in specialty pharma as mid-cap companies expand pipelines.
P&G Acquires Thorne for $3.8B in Major Wellness Market Expansion
Procter & Gamble's $3.8 billion acquisition of Thorne marks a strategic shift as consumer goods giants target the premium supplement sector amid regulatory scrutiny.